title: Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias.
abstract: Alzheimer's disease and related dementias (ADRD) comprise several progressive and incurable neurodegenerative disorders that some have classified as amyloidosis. With increased aging of the world's population, the prevalence of the sporadic form of ADRD, which comprises over 99% of cases, continues to rise at an alarming rate. The enormous societal burdens of ADRD already rival those of the many other major chronic diseases causing premature morbidity and mortality in the USA and worldwide such as cardiovascular disease and cancer. At present, there is an insufficient totality of evidence concerning the efficacy and safety of any pharmacologic agents to delay slow progression or reduce complications of ADRD. In this context, glutaminyl cyclase (QC) inhibitors have shown some early possible evidence of efficacy with a reassuring safety profile. To reliably test the glutaminyl cyclase (QC) and any other promising hypotheses will require cogent data from large-scale randomized trials of sufficient size and duration.
authors.affiliation: a 1 Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Road, Building 71, Suite 337, Boca Raton, FL 33431, USA.
authors.forename: Charles H
authors.initials: CH
authors.lastname: Hennekens
authors.affiliation: a 1 Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Road, Building 71, Suite 337, Boca Raton, FL 33431, USA.
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Bensadon
authors.affiliation: b 2 Department of Medicine, University of Miami Miller School of Medicine, Life Science Bldg 1, Room 3310F, 1600 NW 10th Ave #1140, Miami, FL 33136, USA.|d 4 Translational Research & Alliance Management, Medgenics Inc., 435 Devon Park Drive, Building 700, Wayne, PA 19087, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Zivin
authors.affiliation: c 3 Harvard Medical School, Division on Aging, Brigham and Women's Hospital, 1620 Tremont Street, Boston, MA 02120, USA.
authors.forename: J Michael
authors.initials: JM
authors.lastname: Gaziano
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000453:epidemiology; D019881:Aminoacyltransferases / Q000037:antagonists & inhibitors*; D003704:Dementia / Q000188:drug therapy* / Q000453:epidemiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D014481:United States / Q000453:epidemiology
chemical_list: D004791:Enzyme Inhibitors; D019881:Aminoacyltransferases; C059280:glutaminyl-peptide cyclotransferase
keywords: Alzheimer’s disease and related dementias; glutaminyl cyclase inhibitors; neurotherapeutics; pharmacologic therapies; randomized trials